How to Create a Clinical Trial Project Timeline

Clinical trials span years and involve dozens of parallel workstreams. Here's the Gantt chart template covering protocol design, IRB approval, patient recruitment, data collection, and regulatory submission.

How to Create a Clinical Trial Project Timeline

The Problem: Clinical Trials Are Multi-Year Projects With Zero Tolerance for Slippage

A Phase III clinical trial can take 3–7 years from protocol design to regulatory submission. Within that span, dozens of parallel workstreams must stay synchronized: IRB approvals, site activation, patient recruitment, drug supply, data management, safety monitoring, and statistical analysis. A delay in any one track can cascade — a site that activates late means fewer patients enrolled, which extends the recruitment window, which pushes the database lock, which delays the NDA submission by a year.

Most clinical teams manage these dependencies in spreadsheets that no one trusts and email threads no one can search. The result is missed milestones discovered late, remediation that costs millions, and sponsors who lose competitive advantage in the market window they planned for. gantt-chart.io gives clinical project managers a single shared timeline where every workstream is visible and dependencies between tracks are explicit.

Prerequisites

Protocol synopsis approved by sponsor and medical team
Therapeutic area and phase of trial defined (Phase I, II, or III)
Regulatory strategy agreed (IND submitted or planned, target countries identified)
CRO selected or in-house team assigned with defined responsibilities
Budget and resource plan approved at program level

Clinical Trial Project Timeline Gantt Chart Template

Phase 1: Protocol and Site Preparation (Months 1–6)

[ ] Finalize clinical protocol; complete statistical analysis plan
[ ] Submit Investigational New Drug (IND) application to FDA
[ ] Identify and evaluate potential investigator sites (site feasibility surveys)
[ ] Submit protocol to central IRB/IEC and site-level ethics committees
[ ] Negotiate and execute clinical trial agreements with selected sites
[ ] Set up electronic data capture (EDC) system and randomization platform
[ ] Manufacture and release clinical trial material; arrange drug supply logistics
[ ] Complete investigator meeting; train site staff on protocol and procedures

Phase 2: Site Activation and Recruitment (Months 4–18)

[ ] Activate sites upon IRB approval and regulatory clearance
[ ] Enroll first patient; confirm site processes are working
[ ] Launch patient recruitment campaigns (referral networks, patient registries, digital ads)
[ ] Monitor enrollment rate weekly against target; escalate underperforming sites
[ ] Conduct site monitoring visits per monitoring plan (on-site and remote)
[ ] Manage drug supply to sites; reorder based on enrollment projections
[ ] Review safety data at defined intervals; submit expedited safety reports as required

Phase 3: Data Collection and Monitoring (Months 6–30)

[ ] Perform ongoing data cleaning; resolve queries with site staff within SLA
[ ] Conduct interim analyses per statistical analysis plan; review with DSMB
[ ] Submit annual IND progress reports to FDA
[ ] Manage protocol amendments and distribute updated informed consent forms
[ ] Track patient dropout rates; implement retention strategies at high-dropout sites
[ ] Archive source documents and maintain trial master file (TMF)

Phase 4: Database Lock and Analysis (Months 28–36)

[ ] Complete last patient last visit; confirm all data collected
[ ] Resolve all outstanding data queries; achieve clean database
[ ] Perform database lock; freeze dataset for statistical analysis
[ ] Execute statistical analysis per pre-specified SAP
[ ] Generate clinical study report (CSR); medical review and sign-off
[ ] Prepare NDA/BLA submission package; compile all study data

Phase 5: Regulatory Submission and Close-Out (Months 34–42)

[ ] Submit NDA/BLA to FDA; track receipt and filing date
[ ] Respond to FDA information requests; prepare advisory committee materials if required
[ ] Close out all investigator sites; archive site documents
[ ] Complete pharmacovigilance handoff for post-marketing safety reporting
[ ] Archive all trial data per regulatory retention requirements (15 years)

Common Pitfalls

Optimistic enrollment projections: Sites routinely enroll at 50–70% of projected rates. Build recruitment timelines using historical data from similar trials, not best-case scenarios. Add contingency sites from the start rather than activating them as a rescue measure.
IRB approval as a single event: Central IRB approval does not mean all sites are approved. Site-level additions take weeks. Track each site's activation status individually on the Gantt.
Drug supply not linked to enrollment: Running out of investigational product at a site stops enrollment there. Drug supply planning must be tied directly to the enrollment Gantt, not managed separately.
Database lock treated as a milestone not a workstream: Achieving a clean database requires months of data cleaning. Start cleaning queries from Day 1 of enrollment, not after last patient last visit.

What Good Looks Like

A well-managed clinical trial hits its planned database lock date within 4 weeks of the original projection, has fewer than 5% outstanding queries at lock, and delivers the clinical study report within 6 months of lock. Sites are activated on schedule because agreements were negotiated in parallel with IRB submissions, not sequentially. The Gantt is reviewed weekly by the full project team and monthly by the sponsor, and every milestone has a named owner.